ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc (BMRN)

55,90
1,21
(2,21%)
Geschlossen 23 Juni 10:00PM
55,69
-0,21
( -0,38% )
Vor Marktöffnung: 11:22AM

BioMarin Pharmaceutical Inc (BMRN) Aktie

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Wichtige Statistiken und Details

Current Price
55,69
( -0,38% )
Gebot
55,30
Fragen
57,64
Volumen
752
0,00 Tagesbereich 0,00
49,2592 52-Wochen-Bereich 66,275
Marktkapitalisierung
Handelsende
55,90
Handelsbeginn
-
Letzte Trade
30
@
55.66
Letzter Handelszeitpunkt
10:08:10
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
US$ 1.996.385
Ausgegebene Aktien
193.284.438
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
39,16
Gewinn pro Aktie (EPS)
1,4
Erlöse (LTM)
3,24B
Nettogewinn (LTM)
268,74M

Über BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products i... BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company’s products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California. Mehr anzeigen

Sektor
Healthcare
Branche
Biotechnology & Life Sciences
Hauptsitz
San Rafael, United States
Gegründet
1996
BioMarin Pharmaceutical Inc is listed in the Healthcare sector of the NASDAQ with ticker BMRN. The last closing price for BioMarin Pharmaceutical was US$55,90. Over the last year, BioMarin Pharmaceutical shares have traded in a share price range of US$ 49,2592 to US$ 66,275.

BioMarin Pharmaceutical currently has 193.284.438 shares in issue. The market capitalisation of BioMarin Pharmaceutical is US$10,76 billion. BioMarin Pharmaceutical has a price to earnings ratio (PE ratio) of 39.16.

Option-Flow BioMarin Pharmaceutical (BMRN)

Gesamtfluss

Bullisch

Nettoprämie

29k

Calls / Puts

100,00%

Käuf. / Verkä.

100,00%

OTM / ITM

100,00%

Sweeps

0,00%

BMRN Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.040.071877807726955.6556.5854.26241573855.1893923CS
41.492.7490774907754.258.2652.195232555155.41944803CS
120.7851.4297422821254.90558.2649.2592205633954.50174521CS
26-3.9-6.5447222688459.5966.27549.2592209943256.80746862CS
520.611.1074800290555.0866.27549.2592231570256.25461381CS
156-39.75-41.649203688295.4499.5649.2592192042669.18349423CS
260-25.1-31.068201510180.79117.7749.2592165641275.08800179CS

BMRN - Frequently Asked Questions (FAQ)

What is the current BioMarin Pharmaceutical Inc share price?
The current share price of BioMarin Pharmaceutical Inc is US$ 55,69
How many BioMarin Pharmaceutical Inc shares are in issue?
BioMarin Pharmaceutical Inc has 193.284.438 shares in issue
What is the market cap of BioMarin Pharmaceutical Inc?
The market capitalisation of BioMarin Pharmaceutical Inc is USD 10,76B
What is the 1 year trading range for BioMarin Pharmaceutical Inc share price?
BioMarin Pharmaceutical Inc has traded in the range of US$ 49,2592 to US$ 66,275 during the past year
What is the PE ratio of BioMarin Pharmaceutical Inc?
The price to earnings ratio of BioMarin Pharmaceutical Inc is 39,16
What is the cash to sales ratio of BioMarin Pharmaceutical Inc?
The cash to sales ratio of BioMarin Pharmaceutical Inc is 3,26
What is the registered address of BioMarin Pharmaceutical Inc?
The registered address for BioMarin Pharmaceutical Inc is 770 Lindaro Street, San Rafael, California, 94901
What is the BioMarin Pharmaceutical Inc website address?
The website address for BioMarin Pharmaceutical Inc is www.biomarin.com
Which industry sector does BioMarin Pharmaceutical Inc operate in?
BioMarin Pharmaceutical Inc operates in the Biotechnology & Life Sciences sector

BMRN Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen